Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05224778 · ClinicalTrials.gov registry record

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

A clinical trial of Congenital Myotonic Dystrophy and CDM, sponsored by Virginia Commonwealth University.

Recruiting
Registry status
50
Enrollment target
5
Study locations

NCT05224778 is a study of Congenital Myotonic Dystrophy and CDM that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 50 participants, below the 1,694-participant average among 4 other Congenital Myotonic Dystrophy trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05224778, a study of Congenital Myotonic Dystrophy and CDM, is actively recruiting participants, sponsored by Virginia Commonwealth University.

RECRUITING
Registry status
50 participants
Enrollment target
5
Study locations

Study Summary

The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.

Study Locations (5)

California

  • University of California, Los Angeles - Los Angeles

Kansas

  • University of Kansas Medical Center - Fairway

New York

  • University of Rochester Medical Center - Rochester

Virginia

  • Virginia Commonwealth University - Richmond

Other

  • Centro Clinico NeMO - Milan

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-08-24
Est. Completion 2026-12

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT05224778

The ClinicalTrials.gov registry entry for NCT05224778 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,694-participant average among 4 other Congenital Myotonic Dystrophy trials with a reported enrollment target (97% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Congenital Myotonic Dystrophy appearing as the primary indexed condition, and to 0 interventions.

NCT05224778 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Kansas, New York.

Frequently Asked Questions

What is clinical trial NCT05224778 about?

NCT05224778 is a clinical study titled "DMCRN-02-001: Assessing Pediatric Endpoints in DM1". The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.

What is the current status of trial NCT05224778?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-08-24. Estimated completion is 2026-12.

What conditions does trial NCT05224778 study?

This clinical trial studies the following conditions: Congenital Myotonic Dystrophy, CDM.

Who is sponsoring clinical trial NCT05224778?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05224778 being conducted?

This trial has 5 study locations across California, Kansas, New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Myotonic Dystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.